Clinical Trials

65 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT02114229 2026-03-17

SJATRT

125 enrolled

Rhabdoid Tumor

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT00420563 2026-03-16

PAL-ANGI

Phase 2 Completed

88 enrolled

Tumor-Agnostic

Neoplasms

NCT05468359 2026-03-16

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

64 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT06026319 2026-03-16

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

24 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06186401 2026-03-16

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma

NCT06481735 2026-03-16

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

12 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07194044 2026-03-16

METTSEO

DermatologicGastrointestinalSarcoma

15 enrolled

Sarcoma

Sarcoma, Ewing

NCT01046487 2026-03-13

PALANGI3

Phase 1 Completed

26 enrolled

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

CNSGastrointestinalSarcoma

60 enrolled

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02648282 2026-03-13

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

Phase 2 Completed

58 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04579523 2026-03-13

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma

NCT05453500 2026-03-13

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Burkitt Lymphoma

NCT06738368 2026-03-13

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 1 Not yet recruiting

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07133997 2026-03-13

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

26 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma

NCT01962636 2026-03-12

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Phase NA Recruiting

200 enrolled

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Leukemia, Plasma Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT03970096 2026-03-12

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

LymphoidMyeloidOther hematologic neoplasm

120 enrolled

Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Breast

Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05767359 2026-03-12

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06043323 2026-03-12

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Phase EARLY_PHASE1 Recruiting

Lymphoma, Follicular

NCT06142396 2026-03-12

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Phase 1/2 Not yet recruiting

Multiple Myeloma, Renal Insufficiency

NCT07411599 2026-03-12

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

28 enrolled

Gastrointestinal

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1/2 Completed

55 enrolled 17 charts

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT06623630 2026-03-11

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

16 enrolled

Multiple Myeloma, Renal Insufficiency

NCT06930651 2026-03-11

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

Phase 2 Not yet recruiting

42 enrolled

Myeloid Malignancies

NCT07164469 2026-03-11

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

100 enrolled

Phase 1 Not yet recruiting

Hodgkin Disease

NCT07444632 2026-03-11

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

60 enrolled

Phase 2/3 Not yet recruiting

Hodgkin Disease

NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

116 enrolled

Thoracic

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

NCT06771544 2026-03-10

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

14 enrolled

Dermatologic

Melanoma

NCT07257419 2026-03-10

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

60 enrolled

Recurrence, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

NCT02389309 2026-03-09

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

14 enrolled

Brain Neoplasms

NCT06083922 2026-03-06

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Multiple Myeloma

NCT07454382 2026-03-06

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

26 enrolled

Multiple Myeloma

NCT04375631 2026-03-05

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

MyeloidOther hematologic neoplasm

120 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04510051 2026-03-05

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

18 enrolled

Brain Neoplasms

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

24 enrolled

Burkitt Lymphoma

NCT05736419 2026-03-05

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

24 enrolled

Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06203912 2026-03-05

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

3 enrolled

Multiple Myeloma

NCT03070327 2026-03-04

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Multiple Myeloma

NCT03152318 2026-03-04

rQNestin

62 enrolled

Astrocytoma, Brain Neoplasms, Disease, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma

NCT03849651 2026-03-04

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

69 enrolled 17 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

DermatologicGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Gynecologic

Ovarian Neoplasms

NCT03420963 2026-03-03

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Phase 1 Terminated

12 enrolled

Mesothelioma, Malignant, Bone Neoplasms, Endocrine Gland Neoplasms, Melanoma, Mouth Neoplasms, Pharyngeal Neoplasms, Sarcoma, Skin Neoplasms, Thyroid Neoplasms, Urologic Neoplasms

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled